Driven by Covid-19 fever, Forbion notes investor interest in vaccines and new therapies as part of $557M fund

Kyle Blankenship

Nearly a year into the Covid-19 pandemic, a wave of investment in novel therapies and vaccines to fight the virus has continued to flow—and investors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Driven by Covid-19 fever, Forbion notes investor interest in vaccines and new therapies as part of $557M fund

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Dri­ven by Covid-19 fever, For­bion notes in­vestor in­ter­est in vac­cines and new ther­a­pies as part of $557M fund

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Driven by Covid-19 fever, Forbion notes investor interest in vaccines and new therapies as part of $557M fund